Obstructive Sleep Apnea in Pregnancy
| Status: | Completed |
|---|---|
| Conditions: | Insomnia Sleep Studies, Obesity Weight Loss, Women's Studies, Pulmonary |
| Therapuetic Areas: | Endocrinology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases, Reproductive |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 10/20/2017 |
| Start Date: | February 2015 |
| End Date: | August 2017 |
Obstructive Sleep Apnea in Pregnancy: Development of a Pregnancy-Specific Screening Tool
Obstructive sleep apnea (OSA) is a risk factor for complications during pregnancy and current
screening tools for OSA have not been shown to be reliable in pregnant women. The primary aim
of this study is to develop a valid screening tool to identify at-risk pregnant women, so
that they can be further evaluated and treated. Women with OSA may also be at risk for
respiratory complications related to opiate administration for post-cesarean delivery pain. A
secondary aim of this study is to evaluate post-operative minute ventilation in women who
undergo cesarean delivery using a novel method of non-invasive minute ventilation monitoring.
screening tools for OSA have not been shown to be reliable in pregnant women. The primary aim
of this study is to develop a valid screening tool to identify at-risk pregnant women, so
that they can be further evaluated and treated. Women with OSA may also be at risk for
respiratory complications related to opiate administration for post-cesarean delivery pain. A
secondary aim of this study is to evaluate post-operative minute ventilation in women who
undergo cesarean delivery using a novel method of non-invasive minute ventilation monitoring.
Following recruitment and informed consent, subjects will complete 3 screening questionnaires
for OSA: the Berlin and STOP-BANG questionnaires, and the Epworth Sleepiness Scale. They will
also undergo a physical exam by one of the study investigators including examination of the
neck and upper airway to assess neck circumference, retrognathia, thyromental space, tongue
scalloping, MMS, modified MMS, tonsil size and lateral pharyngeal wall narrowing.
Subjects will all receive ApneaLink™ Air (ResMed, Poway, CA), a FDA-approved, non-invasive,
portable, home polysomnography device, and instructions for using the device during one night
of sleep. They will be given contact information if they have questions regarding use of the
device. Subjects will receive a prepaid FedEx envelope to return the device. They will
receive a parking voucher worth up to a maximum of $7 during this appointment. Subjects will
be compensated ($50 check by mail) once the device is received. A follow-up phone call will
be made by the PI to inform the subject of the results of the home polysomnography study.
Subjects who screen positive (AHI > 5) by home polysomnography will be referred to Duke Sleep
Medicine for further evaluation. Pregnancy outcomes will be followed for all subjects.
Enrolled subjects who go on to have a cesarean delivery will be studied using ExSpiron
(Respiratory Motion, Inc., Waltham, MA), a FDA-approved, non-invasive respiratory volume
monitor for 24 hours. The monitor has three adhesive pads that attach to the chest wall and a
cord that attaches to the monitoring device, similar to an electrocardiogram. The monitor can
be detached and the study suspended when patients ambulate to the restroom, and should not
interfere with breastfeeding. The monitor will be connected to the patient in the
pre-operative holding area, and the monitor will be calibrated with baseline spirometry
measurements using a Wright spirometer over one minute. The subject will wear the device for
the duration of the surgery, in the recovery room, and for 24 following surgery. The
non-invasive respiratory volume monitor will be collected by study personnel at the
conclusion of the 24 hours, and no data collected from the monitor will be used for clinical
decision-making. Standard of care will be followed for the antepartum, intrapartum and
postpartum management of those patients. Patients will continue to be monitored using the
investigators' standard protocol for patients who have received neuraxial morphine which
consists of continuous monitoring for 2 hours, followed by monitoring every 2 hours for 24
hours of the following: vital signs, oxygen saturation, respiratory rate, pain score and
sedation score. The investigators also have nursing standing orders for naloxone
administration for respiratory rate < 8 breaths/min or Richmond Agitation Sedation Scale
(RASS) ≤ -3, together with immediate notification of medical staff, as well an order to
notify medical staff for oxygen saturation < 90% or RASS < -2.
for OSA: the Berlin and STOP-BANG questionnaires, and the Epworth Sleepiness Scale. They will
also undergo a physical exam by one of the study investigators including examination of the
neck and upper airway to assess neck circumference, retrognathia, thyromental space, tongue
scalloping, MMS, modified MMS, tonsil size and lateral pharyngeal wall narrowing.
Subjects will all receive ApneaLink™ Air (ResMed, Poway, CA), a FDA-approved, non-invasive,
portable, home polysomnography device, and instructions for using the device during one night
of sleep. They will be given contact information if they have questions regarding use of the
device. Subjects will receive a prepaid FedEx envelope to return the device. They will
receive a parking voucher worth up to a maximum of $7 during this appointment. Subjects will
be compensated ($50 check by mail) once the device is received. A follow-up phone call will
be made by the PI to inform the subject of the results of the home polysomnography study.
Subjects who screen positive (AHI > 5) by home polysomnography will be referred to Duke Sleep
Medicine for further evaluation. Pregnancy outcomes will be followed for all subjects.
Enrolled subjects who go on to have a cesarean delivery will be studied using ExSpiron
(Respiratory Motion, Inc., Waltham, MA), a FDA-approved, non-invasive respiratory volume
monitor for 24 hours. The monitor has three adhesive pads that attach to the chest wall and a
cord that attaches to the monitoring device, similar to an electrocardiogram. The monitor can
be detached and the study suspended when patients ambulate to the restroom, and should not
interfere with breastfeeding. The monitor will be connected to the patient in the
pre-operative holding area, and the monitor will be calibrated with baseline spirometry
measurements using a Wright spirometer over one minute. The subject will wear the device for
the duration of the surgery, in the recovery room, and for 24 following surgery. The
non-invasive respiratory volume monitor will be collected by study personnel at the
conclusion of the 24 hours, and no data collected from the monitor will be used for clinical
decision-making. Standard of care will be followed for the antepartum, intrapartum and
postpartum management of those patients. Patients will continue to be monitored using the
investigators' standard protocol for patients who have received neuraxial morphine which
consists of continuous monitoring for 2 hours, followed by monitoring every 2 hours for 24
hours of the following: vital signs, oxygen saturation, respiratory rate, pain score and
sedation score. The investigators also have nursing standing orders for naloxone
administration for respiratory rate < 8 breaths/min or Richmond Agitation Sedation Scale
(RASS) ≤ -3, together with immediate notification of medical staff, as well an order to
notify medical staff for oxygen saturation < 90% or RASS < -2.
Inclusion Criteria:
- gestational age 24 to 35 weeks
- BMI > or equal to 40 kg/m2
- 18 years or older
Exclusion Criteria:
- Non-English speaking subjects
- Established diagnosis of OSA
- chronic narcotic use
We found this trial at
1
site
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Jennifer E Dominguez, MD
Phone: 919-970-8230
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
